Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses
Authors: Rodriguez-Rosario Alanis Enid , Acosta Medina Aldo Adrian , Bennani N. Nora , Goyal Gaurav , Ravindran Aishwarya , Rech Karen L , Ruan Gordon J , Shah Mithun V , Yi Dongni , Zanwar Saurabh , Abeykoon Jithma P , Go Ronald S 
Published: December 2024

Introduction. Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH) and Rosai-Dorfman disease (RDD) belong to a group of histiocytic neoplasms often driven by mutations in the mitogen activated protein kinase (MAPK) pathway, most commonly in BRAF, MAP2K1 and K/NRAS. Currently, there are 2 drugs approved by the US Food and Drug Administration for the treatment of histiocytic neoplasms, cobimetinib and vemurafenib, both small molecule kinase inhibitors (SMKI) targeting mitogen-activated extracellular signal-regulated kinase (MEK) and BRAF, respectively. BRAF mutations are functionally classified as RAS-independent - either monomers (class I) or dimers (class II) - and RAS-dependent (class III). MAP2K1 mutations are functionally classified as RAF-independent, RAF-regulated, or RAF-dependent. Preclinical studies suggest class I, but not classes II-III, BRAF mutations are sensitive to RAF monomer inhibitors (dabrafenib, encorafenib, vemurafenib) while classes I-II, but not class III, BRAF mutations are sensitive to MEK inhibitors (Yaeger R, Cancer Discovery 2019). In contrast, RAF-regulated MAP2K1 mutants have variable sensitivities to allosteric MEK inhibitors (binimetinib, cobimetinib, selumetinib, trametinib) while RAF-dependent and RAF-independent MAP2K1 mutations are resistant. KRAS mutations are generally resistant to MEK inhibitors (Johnson C, Cancer Discovery 2022). Our study described the clinical efficacy of commercially available SMKIs in patients with histiocytic neoplasms harboring non-BRAFV600E mutations and compared the findings with preclinical data.
Methods. We conducted a retrospective chart review of patients with histiocytic neoplasms who were treated with SMKI at Mayo Clinic. Only those who had adequate genomic testing and non-BRAFV600E mutations were included. Responses were categorized as complete (CR), partial (PR), or none (NR) based on established criteria.
Results. We identified 31 non-BRAFV600E patients treated with SMKI (2 LCH; 20 ECD; 9 RDD). The median age at diagnosis was 61 years (range: 16-76) and 52% were females. The distribution of BRAF mutations was: class I (V600delinsRE [1]), class II (V495A [1], V471F [1], N486_P490del [2], GAB2-BRAF [1], UBR2-BRAF [1], RNF11-BRAF [1], UBTD2-BRAF [1]), and class III (G466E [1], D594A [1]). The only patient with class I mutation received cobimetinib and had PR. Among those with BRAF class II mutations, 2 received vemurafenib and had NR, while 9 received MEK inhibitors (binimetinib, cobimetinib, trametinib) and most responded (3 CRs, 5 PRs). The patient who had NR required dose reductions due to side effects. Both patients with class III mutation did not respond to cobimetinib. The median duration of responses was 19 months (range: 3+ to 45+) and 3 patients progressed subsequently. The distribution of MAP2K1 mutations was: RAF-independent (E102_103del [2]), RAF-regulated (I103N [1], K57T [1], Q56P [3], F53L [1], K57N [1]) and RAF-dependent (Y130C [1], D67N [1]). Both patients with RAF-independent mutations treated with cobimetinib had PRs. All patients with RAF-regulated mutations treated with allosteric MEK inhibitors responded (3 CRs, 5 PRs). Both patients with RAF-dependent mutations treated with cobimetinib responded (1 CR, 1 PR). The median duration of responses was 15 months (2 to 29+) with 3 patients progressing after treatment cessation due to intolerance. The distribution of RAS mutations was: NRAS (Q16R [1]) and KRAS (K117N [3], A146T [1], T581 [1], G13C [1], G12D [1]). Most patients treated with allosteric MEK inhibitors responded (3 CR, 4 PR, 1 NR). The median duration of response was 15 months (5 to 41) and 2 patients subsequently progressed, one of them after treatment cessation.
Conclusions. Among patients with histiocytic neoplasms with non-BRAFV600E mutations receiving SMKI, our study found mixed patterns of concordance between pre-clinical predictions and clinical responses. There was concordance of efficacy in the setting of BRAF classes I-III and MAP2K1 RAF-regulated mutations. However, we found discordant findings in patients harboring RAF-dependent and RAF-independent MAP2K1 mutations as well as KRAS mutations as most responded to allosteric MEK inhibitors.